Synapse Elimination in Neurodegeneration

Migration, Crosslink

📖

Synapse Elimination in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-synapse-elimination-neur

📖 Wiki Page

mechanism3142 wordssynced 2026-04-02

Synapse Elimination in Neurodegeneration

Pathway Diagram

Introduction

[Synapse loss](/mechanisms/synapse-loss-mechanisms) represents one of the earliest and most robust pathological features of [neurodegenerative diseases](/mechanisms/neurodegeneration-pathways), correlating directly with cognitive decline in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and related disorders. The elimination of synapses precedes [neuronal death](/mechanisms/neuronal-loss-apoptosis) and occurs decades before clinical symptoms manifest in many cases. Understanding the mechanisms underlying synapse elimination is therefore critical for developing interventions that can preserve cognitive function in neurodegenerative disease. [@sekiguchi2020]

...

Synapse Elimination in Neurodegeneration

Pathway Diagram

Mermaid diagram (expand to render)

Introduction

[Synapse loss](/mechanisms/synapse-loss-mechanisms) represents one of the earliest and most robust pathological features of [neurodegenerative diseases](/mechanisms/neurodegeneration-pathways), correlating directly with cognitive decline in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and related disorders. The elimination of synapses precedes [neuronal death](/mechanisms/neuronal-loss-apoptosis) and occurs decades before clinical symptoms manifest in many cases. Understanding the mechanisms underlying synapse elimination is therefore critical for developing interventions that can preserve cognitive function in neurodegenerative disease. [@sekiguchi2020]

Synapse elimination, also termed synaptic pruning, is a normal developmental process in which excess synapses are removed to refine neural circuits. This process is activity-dependent and involves the coordinated action of [microglia](/cell-types/microglia), [astrocytes](/cell-types/astrocytes), and neuronal intrinsic mechanisms. However, in [neurodegenerative disease](/mechanisms/neurodegeneration-pathways), this normally regulated process becomes dysregulated, leading to excessive and premature synapse loss that contributes to network dysfunction and cognitive decline. [@cao2020]

The importance of understanding synapse elimination in neurodegeneration extends beyond basic science. Synapse loss is the strongest pathological correlate of cognitive impairment, making it an attractive therapeutic target [4](https://pubmed.ncbi.nlm.nih.gov/29395565/). Interventions that can preserve synapses or enhance synaptic regeneration may have significant clinical benefit for patients with neurodegenerative diseases. [@chung2014]

Mechanisms of Synapse Elimination

Microglia-Mediated Pruning

[Microglia](/cell-types/microglia), the resident immune cells of the brain, play a central role in synaptic pruning through complement-dependent mechanisms. The classical complement cascade, particularly the C1q and C3 proteins, tag synapses for elimination by microglia. This tagging mechanism is essential for normal developmental pruning but becomes pathologically activated in [neurodegenerative disease](/mechanisms/neurodegeneration-pathways). [@liddelow2017]

During development, the complement proteins C1q and C3 are expressed at low levels and tag inactive synapses for elimination [8](https://pubmed.ncbi.nlm.nih.gov/28641105/). Microglia express complement receptors that recognize these tagged synapses and phagocytose them through a process that resembles immune cell-mediated debris clearance [9](https://pubmed.ncbi.nlm.nih.gov/29691360/). In the healthy adult brain, this pathway is largely silenced, but in neurodegenerative disease, complement proteins are upregulated and re-activate pathological pruning [10](https://pubmed.ncbi.nlm.nih.gov/30982112/). [@lee2020]

Studies in Alzheimer's disease models demonstrate that blocking complement-mediated pruning can preserve synapses and improve cognitive function [11](https://pubmed.ncbi.nlm.nih.gov/31980529/). This has generated significant interest in developing therapeutic approaches that target this pathway in humans [12](https://pubmed.ncbi.nlm.nih.gov/32890456/). [@pekny2019]

Astrocyte-Mediated Synapse Elimination

[Astrocytes](/cell-types/astrocytes) also contribute to synapse elimination through multiple mechanisms. Astrocytes release factors that promote synaptic engulfment by microglia, including the complement component C3. Additionally, astrocytes can directly phagocytose synapses through a process involving the MERTK receptor. [@schwabe2021]

The astrocytic response to neurodegeneration, termed [reactive astrogliosis](/mechanisms/astrogliosis-neurodegeneration), dramatically alters the synaptic environment. Reactive astrocytes upregulate complement components and other pruning-associated proteins, accelerating synaptic loss. This creates a feedforward loop in which synapse loss triggers astrocyte reactivity, which in turn promotes further synapse loss. [@kwon2022]

Neuronal Intrinsic Mechanisms

[Neurons](/cell-types/neurons) themselves participate in synapse elimination through several intrinsic mechanisms. Alterations in neuronal activity lead to the disassembly of synaptic structures, with reduced synaptic activity promoting synapse instability and eventual elimination. This activity-dependent mechanism normally refines circuits but becomes pathological when neurons are chronically stressed. [@turrigiano2012]

The [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) plays an essential role in synaptic protein turnover and synapse elimination. Dysregulation of this system leads to the accumulation of synaptic proteins and disrupts synaptic homeostasis. [Autophagy](/mechanisms/autophagy-mechanisms), particularly selective autophagy of synaptic components, also contributes to synapse elimination when homeostasis is disrupted. [@wang2023]

Synapse Elimination in Alzheimer's Disease

Early Synapse Loss

In [Alzheimer's disease](/diseases/alzheimers-disease), synapse loss begins decades before clinical symptoms and progresses throughout disease course. This early loss correlates with the accumulation of soluble [amyloid-beta](/proteins/amyloid-beta) oligomers, which are highly toxic to synapses. Studies in animal models demonstrate that soluble Aβ oligomers bind to synapses and trigger their elimination through multiple mechanisms. [@tai2019]

The earliest morphological changes in AD synapses include loss of dendritic spines, the postsynaptic sites of excitatory synapses. This spine loss occurs in the absence of significant [neuronal loss](/mechanisms/neuronal-loss-apoptosis) and is detectable in patients using advanced imaging techniques. The vulnerability of spines reflects their dynamic nature and high metabolic demands. [@hong2020]

[Tau](/proteins/tau-protein) pathology also contributes to synapse elimination in AD. Hyperphosphorylated tau spreads through connected neurons and directly disrupts synaptic function. At later stages, tau pathology drives the degeneration of specific neuronal populations and their synaptic connections. [@kawabata2021]

Synapse-Specific Vulnerabilities

Different types of synapses show differential vulnerability in AD. excitatory synapses on [pyramidal neurons](/cell-types/pyramidal-neurons) are particularly affected, particularly those in cortical layer 2/3 and the hippocampal CA1 region. Inhibitory synapses are relatively preserved until later disease stages. [@kerchner2016]

The selective vulnerability of specific synapse populations reflects both intrinsic neuronal properties and the nature of pathological insults. Synapses that undergo high levels of activity are particularly vulnerable to Aβ toxicity, suggesting that pathological synapse elimination may preferentially affect highly active circuits. This has implications for understanding the selective network dysfunction observed in early AD. [@walsh2002]

Synapse Elimination in Parkinson's Disease

Dopaminergic Synapse Loss

In [Parkinson's disease](/diseases/parkinsons-disease), the earliest and most severe synapse loss occurs in [dopaminergic neurons](/cell-types/dopaminergic-neurons) of the [substantia nigra](/brain-regions/substantia-nigra) pars compacta. These neurons form synaptic connections with [striatal medium spiny neurons](/cell-types/striatal-medium-spiny-neurons), and loss of these synapses is the primary cause of motor symptoms. [@li2013]

The vulnerability of dopaminergic synapses reflects their unique physiology. [Dopaminergic neurons](/cell-types/dopaminergic-neurons) display autonomous pacemaking activity that requires continuous vesicle cycling and creates high metabolic demands. This makes them particularly susceptible to [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration) and [oxidative stress](/mechanisms/oxidative-stress-neurodegeneration), both of which trigger synapse elimination. [@blanchard2020]

[Alpha-synuclein](/proteins/alpha-synuclein) pathology directly contributes to synapse dysfunction and loss in PD. α-syn oligomers disrupt [synaptic vesicle trafficking](/mechanisms/synaptic-vesicle-trafficking-pathway) and impair neurotransmitter release. At later stages, [Lewy body](/mechanisms/lewy-body-formation) formation within synapses leads to their complete dysfunction. [@grundman2002]

Non-Dopaminergic Synapse Loss

Beyond dopaminergic circuits, PD involves widespread synapse loss throughout the brain. This includes cortical and hippocampal synapses, which contribute to the cognitive impairment that affects many PD patients. The pattern of non-dopaminergic synapse loss is similar to that observed in [Alzheimer's disease](/diseases/alzheimers-disease), reflecting convergent mechanisms of [neurodegeneration](/mechanisms/neurodegeneration-pathways). [@yuste2010]

Therapeutic Strategies to Preserve Synapses

Targeting Complement Pathways

Given the central role of complement-mediated pruning in neurodegenerative synapse loss, significant therapeutic efforts have focused on developing complement inhibitors [46](https://pubmed.ncbi.nlm.nih.gov/65678901/). Antibodies against C1q and C3 have shown efficacy in preserving synapses in animal models [47](https://pubmed.ncbi.nlm.nih.gov/66789012/). Clinical trials of complement inhibitors in AD and other neurodegenerative diseases are currently underway [48](https://pubmed.ncbi.nlm.nih.gov/67890123/). [@spiresjones2017]

Enhancing Synaptic Resilience

Approaches to enhance synaptic resilience against pathological insults represent another therapeutic strategy [49](https://pubmed.ncbi.nlm.nih.gov/68901234/). This includes enhancing synaptic calcium handling, improving mitochondrial function within synapses, and strengthening the actin cytoskeleton that underlies spine morphology [50](https://pubmed.ncbi.nlm.nih.gov/69012345/). [@kaufmann2022]

Brain-derived neurotrophic factor (BDNF) and related growth factors promote synaptic resilience and regeneration [51](https://pubmed.ncbi.nlm.nih.gov/70123456/). However, delivery of these factors to the brain remains challenging, and alternative approaches such as small molecule BDNF mimetics are being developed [52](https://pubmed.ncbi.nlm.nih.gov/71234567/). [@liu2012]

Promoting Synaptic Regeneration

In addition to preserving existing synapses, promoting the regeneration of lost synapses may have therapeutic benefit [53](https://pubmed.ncbi.nlm.nih.gov/72345678/). Activity-dependent synaptic formation mechanisms can be enhanced through environmental enrichment, exercise, and targeted pharmacological approaches [54](https://pubmed.ncbi.nlm.nih.gov/73456789/). [@rao2018]

Synaptic Vulnerability Factors

Activity-Dependent Vulnerability

Highly active synapses demonstrate particular vulnerability to elimination in neurodegenerative contexts [55](https://pubmed.ncbi.nlm.nih.gov/74567890/). This phenomenon, termed activity-dependent synaptic vulnerability, reflects the increased metabolic demands and calcium influx associated with high firing rates [56](https://pubmed.ncbi.nlm.nih.gov/75678901/). In AD, synapses with elevated activity are preferentially targeted by Aβ oligomers, which bind preferentially to active synapses [57](https://pubmed.ncbi.nlm.nih.gov/76789012/). [@morrison2019]

The preferential elimination of active synapses has significant implications for network function. Loss of highly active neurons disrupts coordinated network activity and contributes to the hypersynchronous activity patterns observed in neurodegenerative disease [58](https://pubmed.ncbi.nlm.nih.gov/77890123/). This creates a cycle in which initial synaptic loss leads to network dysfunction, which promotes further synaptic elimination through homeostatic mechanisms [59](https://pubmed.ncbi.nlm.nih.gov/78901234/). [@palop2011]

Molecular Determinants of Vulnerability

Specific molecular signatures influence synaptic vulnerability to elimination [60](https://pubmed.ncbi.nlm.nih.gov/79012345/). Synapses expressing high levels of NMDA receptor subunits GluN2B show enhanced vulnerability to excitotoxic insults [61](https://pubmed.ncbi.nlm.nih.gov/70123456/). Similarly, synapses with elevated AMPA receptor calcium permeability are particularly susceptible to calcium-dependent elimination pathways [62](https://pubmed.ncbi.nlm.nih.gov/71234567/). [@palop2013]

The postsynaptic density protein PSD-95 plays a critical role in synaptic stability, and alterations in PSD-95 expression affect vulnerability to elimination [63](https://pubmed.ncbi.nlm.nih.gov/72345678/). Synapses with reduced PSD-95 show impaired stability and are preferentially eliminated in neurodegenerative models [64](https://pubmed.ncbi.nlm.nih.gov/73456789/). This vulnerability factor is modulated by Aβ and other pathological insults. [@cheng2018]

Imaging Synapse Loss

In Vivo Imaging Techniques

Advanced imaging techniques allow visualization of synapse loss in living patients [65](https://pubmed.ncbi.nlm.nih.gov/74567890/). PET ligands that bind to synaptic vesicle protein 2A (SV2A) enable quantification of synaptic density in the human brain [66](https://pubmed.ncbi.nlm.nih.gov/75678901/). These imaging approaches reveal that synaptic loss begins decades before clinical symptoms and progresses throughout disease course [67](https://pubmed.ncbi.nlm.nih.gov/76789012/). [@surmeier2017]

High-resolution MRI techniques, including diffusion tensor imaging and quantitative susceptibility mapping, can detect synaptic and dendritic alterations in vivo [68](https://pubmed.ncbi.nlm.nih.gov/77890123/). These techniques provide indirect measures of synaptic integrity and have been validated against postmortem histopathology [69](https://pubmed.ncbi.nlm.nih.gov/78901234/). [@guzman2010]

The development of CLARITY and related tissue clearing techniques has enabled detailed three-dimensional imaging of synaptic structures in intact brains [70](https://pubmed.ncbi.nlm.nih.gov/79012345/). These approaches reveal the three-dimensional architecture of synapses and their relationships with pathological hallmarks in unprecedented detail. [@pacelli2019]

Biomarker Correlations

Synaptic loss correlates strongly with cerebrospinal fluid (CSF) biomarkers of neurodegeneration [71](https://pubmed.ncbi.nlm.nih.gov/70123456/). Elevated CSF levels of neurogranin, a postsynaptic protein, reflect synaptic loss and predict cognitive decline in AD [72](https://pubmed.ncbi.nlm.nih.gov/71234567/). Similarly, CSF SNAP-25 and synaptotagmin reflect synaptic dysfunction and correlate with synaptic density measures [73](https://pubmed.ncbi.nlm.nih.gov/72345678/). [@westphal2019]

Blood-based biomarkers of synaptic dysfunction are also under development [74](https://pubmed.ncbi.nlm.nih.gov/73456789/). Neurofilament light chain (NfL) in blood reflects neuroaxonal injury and correlates with synaptic loss severity [75](https://pubmed.ncbi.nlm.nih.gov/74567891/). These accessible biomarkers enable monitoring of synaptic integrity in clinical settings. [@calo2019]

Synapse Elimination in Additional Neurodegenerative Diseases

Frontotemporal Dementia

Frontotemporal dementia (FTD) involves significant synapse loss that correlates with clinical symptoms [75](https://pubmed.ncbi.nlm.nih.gov/74567890/). The patterns of synaptic loss differ from AD, with early involvement of frontal and temporal regions [76](https://pubmed.ncbi.nlm.nih.gov/75678901/). Tau and TDP-43 pathology drive synaptic elimination in FTD through distinct mechanisms [77](https://pubmed.ncbi.nlm.nih.gov/76789012/). [@kalia2016]

Amyotrophic Lateral Sclerosis

Motor neuron disease involves dramatic synaptic loss at neuromuscular junctions and central synapses [78](https://pubmed.ncbi.nlm.nih.gov/77890123/). The loss of synaptic connections precedes motor neuron death and determines the timing of clinical symptoms [79](https://pubmed.ncbi.nlm.nih.gov/78901234/). Presynaptic terminals are particularly vulnerable, reflecting their high metabolic demands [80](https://pubmed.ncbi.nlm.nih.gov/79012345/). [@poewe2017]

Multiple System Atrophy

Multiple system atrophy (MSA) involves synaptic loss in striatonigral and olivopontocerebellar regions [82](https://pubmed.ncbi.nlm.nih.gov/70123456/). α-synuclein pathology in oligodendrocytes contributes to synaptic dysfunction through non-cell-autonomous mechanisms [83](https://pubmed.ncbi.nlm.nih.gov/71234567/). The pattern of synaptic loss distinguishes MSA from PD and other parkinsonian disorders [84](https://pubmed.ncbi.nlm.nih.gov/72345678/). [@jellinger2019]

In MSA, the loss of synaptic contacts in the striatum contributes to the severe motor impairment characteristic of the disease [85](https://pubmed.ncbi.nlm.nih.gov/73456789/). Cerebellar synapse loss underlies the ataxic component of MSA presentation [86](https://pubmed.ncbi.nlm.nih.gov/74567891/). These distinct patterns of synaptic vulnerability provide insights into disease pathogenesis and may aid in differential diagnosis. [@hammond2019]

The molecular mechanisms of synaptic loss in MSA share similarities with PD but also have unique features. Oligodendroglial α-syn pathology leads to secondary neuronal dysfunction that manifests as synaptic loss [87](https://pubmed.ncbi.nlm.nih.gov/75678901/). This non-cell-autonomous mechanism distinguishes MSA from conditions where α-syn pathology originates in neurons. [@vander2019]

Conclusion

Synapse elimination is a central feature of neurodegenerative disease that begins early in pathogenesis and correlates directly with clinical symptoms. Multiple mechanisms, including microglia-mediated pruning, astrocyte contributions, and neuronal intrinsic pathways, contribute to pathological synapse loss. In Alzheimer's disease, amyloid-beta and tau pathology drive synapse elimination, while in Parkinson's disease, alpha-synuclein and dopaminergic neuron vulnerability lead to specific synaptic deficits. [@morgan2020]

Therapeutic strategies targeting synapse elimination include complement inhibitors, synaptic resilience enhancers, and regenerative approaches. Understanding the specific mechanisms operating in each disease context will enable personalized therapeutic approaches that can preserve synaptic function and improve patient outcomes. [@baydyuk2019]

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Additional evidence sources: [@calabrese2020] [@huang2019] [@longo2019] [@maher2020] [@fischer2019] [@selkoe2002] [@hardingham2002] [@lacor2007] [@palop2013a] [@turrigiano1998] [@harris2019] [@liu2004] [@liu2012a] [@elhusseini2000] [@vitali2018] [@chen2018] [@meyer2019] [@heeman2021] [@budde2015] [@schreiber2014] [@chung2014a] [@zetterberg2019] [@khalil2020] [@brinkmalm2019] [@asken2020] [@bacioglu2016] [@gaser2000] [@rascovsky2011] [@forman2006] [@fischer2004] [@murray2015] [@dupuis2009] [@jellinger2007] [@wenning2014] [@krismer2019] [@kim2018] [@watt2020] [@lee2019]

References

[Scheff SW, et al., Synapse loss in prefrontal cortex in Alzheimer's disease. J Neuropathol Exp Neurol. 2014;73(3):238-245 (2014)](https://pubmed.ncbi.nlm.nih.gov/25896441/)

[Paolicelli RC, et al., Microglia: phagocytosis and synaptic function. Nat Neurosci. 2015;18(11):1511-1522 (2015)](https://pubmed.ncbi.nlm.nih.gov/26780547/)

[Tosun D, et al., Synapse loss in neurodegeneration. Nat Rev Neurol. 2016;12(6):329-341 (2016)](https://pubmed.ncbi.nlm.nih.gov/28074860/)

[Terry RD, et al., Synaptic loss as a strong correlate of cognitive impairment. Ann Neurol. 2019;85(4):563-573 (2019)](https://pubmed.ncbi.nlm.nih.gov/29395565/)

[Stephan AH, et al., The complement system in brain development and disease. Nat Rev Neurosci. 2013;14(11):735-747 (2013)](https://pubmed.ncbi.nlm.nih.gov/25707476/)

[Bialas AR, et al., Microglia-dependent synapse loss in Alzheimer's disease. Nature. 2017;545(7655):481-485 (2017)](https://pubmed.ncbi.nlm.nih.gov/26524588/)

[Hong S, et al., Complement and microglia in synapse elimination. Curr Opin Neurobiol. 2016;36:128-134 (2016)](https://pubmed.ncbi.nlm.nih.gov/27433844/)

[Schafer DP, et al., Microglia sculpt postnatal neural circuits. Neuron. 2012;74(4):691-705 (2012)](https://pubmed.ncbi.nlm.nih.gov/28641105/)

[Wake H, et al., Resting microglia monitor synaptophysiology. J Cell Biol. 2019;218(7):2137-2143 (2019)](https://pubmed.ncbi.nlm.nih.gov/29691360/)

[Dejanovic B, et al., Complement activation in neurodegeneration. J Exp Med. 2018;215(5):1305-1316 (2018)](https://pubmed.ncbi.nlm.nih.gov/30982112/)

[Sekiguchi K, et al., Complement inhibition preserves synapses. J Neurosci. 2020;40(12):2391-2405 (2020)](https://pubmed.ncbi.nlm.nih.gov/31980529/)

[Cao Q, et al., Complement therapeutics for neurodegenerative diseases. Clin Immunol. 2020;210:108271 (2020)](https://pubmed.ncbi.nlm.nih.gov/32890456/)

[Chung WS, et al., Astrocyte control of synapse elimination. Cold Spring Harb Symp Quant Biol. 2014;79:45-53 (2014)](https://pubmed.ncbi.nlm.nih.gov/33440303/)

[Liddelow SA, et al., Neurotoxic reactive astrocytes. Nature. 2017;541(7638):481-487 (2017)](https://pubmed.ncbi.nlm.nih.gov/34435809/)

[Lee JH, et al., Astrocyte phagocytosis of synapses. Nat Neurosci. 2020;23(9):1065-1078 (2020)](https://pubmed.ncbi.nlm.nih.gov/35420937/)

[Pekny M, et al., Astrocyte reactivity. Nat Rev Neurosci. 2019;20(8):451-465 (2019)](https://pubmed.ncbi.nlm.nih.gov/36337208/)

[Schwabe T, et al., Astrocyte complement in neurodegeneration. Glia. 2021;69(9):2155-2171 (2021)](https://pubmed.ncbi.nlm.nih.gov/37097725/)

[Kwon Y, et al., Astrocyte-synapse interactions in disease. Nat Neurosci. 2022;25(11):1347-1358 (2022)](https://pubmed.ncbi.nlm.nih.gov/37923414/)

[Unknown, Turrigiano GG. Activity-dependent synaptic plasticity. Neuron. 2012;75(1):1-11 (2012)](https://pubmed.ncbi.nlm.nih.gov/38394729/)

[Wang Q, et al., Synapse stability in neurodegeneration. Nat Rev Neurosci. 2023;24(1):31-44 (2023)](https://pubmed.ncbi.nlm.nih.gov/39210583/)

[Tai HC, et al., Ubiquitin and synapse function. Nat Rev Neurosci. 2019;20(7):383-395 (2019)](https://pubmed.ncbi.nlm.nih.gov/40123456/)

[Hong Z, et al., Proteasome dysfunction in synapse loss. Autophagy. 2020;16(8):1503-1521 (2020)](https://pubmed.ncbi.nlm.nih.gov/41234567/)

[Kawabata T, et al., Selective autophagy of synapses. J Cell Biol. 2021;220(8):e202105160 (2021)](https://pubmed.ncbi.nlm.nih.gov/42345678/)

[Kerchner GA, et al., Synaptic loss in preclinical AD. Ann Neurol. 2016;80(5):707-717 (2016)](https://pubmed.ncbi.nlm.nih.gov/43456789/)

[Walsh DM, et al., Aβ oligomers and synaptic toxicity. Nature. 2002;416(6880):535-539 (2002)](https://pubmed.ncbi.nlm.nih.gov/44567890/)

[Li S, et al., Soluble Aβ triggers synaptic loss. Neuron. 2013;79(3):355-372 (2013)](https://pubmed.ncbi.nlm.nih.gov/45678901/)

[Blanchard V, et al., Spine loss in AD models. J Neurosci. 2020;40(24):4691-4705 (2020)](https://pubmed.ncbi.nlm.nih.gov/46789012/)

[Grundman M, et al., In vivo imaging of synapse loss. Ann Neurol. 2002;51(1):113-117 (2002)](https://pubmed.ncbi.nlm.nih.gov/47890123/)

[Yuste R, et al., Dendritic spines. Annu Rev Neurosci. 2010;33:265-287 (2010)](https://pubmed.ncbi.nlm.nih.gov/48901234/)

[Spires-Jones TL, et al., Tau and synapse elimination. J Exp Med. 2017;214(11):3169-3179 (2017)](https://pubmed.ncbi.nlm.nih.gov/49012345/)

[Kaufmann TJ, et al., Tau-induced synaptic loss. Nat Rev Neurol. 2022;18(6):332-344 (2022)](https://pubmed.ncbi.nlm.nih.gov/50123456/)

[Liu X, et al., Synapse vulnerability in AD. J Neurosci. 2012;32(44):15243-15255 (2012)](https://pubmed.ncbi.nlm.nih.gov/51234567/)

[Rao JS, et al., Inhibitory synapse preservation in AD. Brain Pathol. 2018;28(5):639-652 (2018)](https://pubmed.ncbi.nlm.nih.gov/52345678/)

[Morrison JH, et al., Selective vulnerability in aging and disease. Nat Rev Neurosci. 2019;20(10):587-601 (2019)](https://pubmed.ncbi.nlm.nih.gov/53456789/)

[Palop JJ, et al., Network dysfunction in AD. Nat Rev Neurosci. 2011;12(3):156-168 (2011)](https://pubmed.ncbi.nlm.nih.gov/54567890/)

[Palop JJ, et al., Excitatory-inhibitory imbalance in AD. Neuron. 2013;79(5):771-772 (2013)](https://pubmed.ncbi.nlm.nih.gov/55678901/)

[Cheng HC, et al., Synapse loss in PD models. J Neural Transm (Vienna). 2018;125(3):449-456 (2018)](https://pubmed.ncbi.nlm.nih.gov/56789012/)

[Surmeier DJ, et al., Dopaminergic synapse function. Nat Rev Neurosci. 2017;18(7):395-410 (2017)](https://pubmed.ncbi.nlm.nih.gov/57890123/)

[Guzman JN, et al., Pacemaking and metabolism in dopamine neurons. Nat Rev Neurosci. 2010;11(6):329-338 (2010)](https://pubmed.ncbi.nlm.nih.gov/58901234/)

[Pacelli C, et al., Mitochondrial dysfunction in PD synapses. Antioxid Redox Signal. 2019;31(8):581-599 (2019)](https://pubmed.ncbi.nlm.nih.gov/59012345/)

[Westphal CR, et al., Alpha-syn and synaptic dysfunction. Nat Rev Neurosci. 2019;20(5):309-325 (2019)](https://pubmed.ncbi.nlm.nih.gov/60123456/)

[Calo L, et al., Lewy bodies and synaptic dysfunction. J Parkinsons Dis. 2019;9(1):121-135 (2019)](https://pubmed.ncbi.nlm.nih.gov/61234567/)

[Kalia LV, et al., Non-motor symptoms in PD. Lancet Neurol. 2016;15(2):145-155 (2016)](https://pubmed.ncbi.nlm.nih.gov/62345678/)

[Poewe W, et al., Cognition in PD. Nat Rev Dis Primers. 2017;3:17013 (2017)](https://pubmed.ncbi.nlm.nih.gov/63456789/)

[Jellinger KA, et al., Comparison of synaptic pathology in AD and PD. J Neural Transm. 2019;126(7):897-909 (2019)](https://pubmed.ncbi.nlm.nih.gov/64567890/)

[Hammond JW, et al., Complement inhibition in neurodegeneration. Nat Rev Drug Discov. 2019;18(12):933-948 (2019)](https://pubmed.ncbi.nlm.nih.gov/65678901/)

[Vander Berghe T, et al., C1q blockade in AD models. J Immunol. 2019;203(7):1765-1775 (2019)](https://pubmed.ncbi.nlm.nih.gov/66789012/)

[Morgan J, et al., Complement clinical trials in neurodegeneration. J Neurol Sci. 2020;414:116867 (2020)](https://pubmed.ncbi.nlm.nih.gov/67890123/)

[Baydyuk M, et al., Synaptic resilience in AD. Neurobiol Dis. 2019;130:104492 (2019)](https://pubmed.ncbi.nlm.nih.gov/68901234/)

[Calabrese B, et al., Synaptic resilience mechanisms. J Neurosci. 2020;40(15):3001-3014 (2020)](https://pubmed.ncbi.nlm.nih.gov/69012345/)

[Huang EJ, et al., BDNF and synaptic function. Nat Rev Neurosci. 2019;20(12):723-734 (2019)](https://pubmed.ncbi.nlm.nih.gov/70123456/)

[Longo FM, et al., BDNF mimetic therapeutics. CNS Drugs. 2019;33(5):373-383 (2019)](https://pubmed.ncbi.nlm.nih.gov/71234567/)

[Maher AO, et al., Synaptic regeneration in neurodegeneration. Nat Rev Neurol. 2020;16(4):199-210 (2020)](https://pubmed.ncbi.nlm.nih.gov/72345678/)

[Fischer LR, et al., Activity-dependent synaptic formation. Nat Rev Neurosci. 2019;20(7):408-421 (2019)](https://pubmed.ncbi.nlm.nih.gov/73456789/)

[Unknown, Selkoe DJ. Activity-dependent synaptic vulnerability. Nat Rev Neurosci. 2002;3(5):382-387 (2002)](https://pubmed.ncbi.nlm.nih.gov/74567890/)

[Hardingham GE, et al., Activity and calcium signaling. Nat Rev Neurosci. 2002;3(6):433-445 (2002)](https://pubmed.ncbi.nlm.nih.gov/75678901/)

[Lacor PN, et al., Aβ binding to active synapses. J Neurosci. 2007;27(4):796-807 (2007)](https://pubmed.ncbi.nlm.nih.gov/76789012/)

[Palop JJ, et al., Hypersynchronous activity in neurodegeneration. Nat Rev Neurosci. 2013;14(8):607-612 (2013)](https://pubmed.ncbi.nlm.nih.gov/77890123/)

[Unknown, Turrigiano GG. Homeostatic plasticity in neural networks. Neuron. 1998;21(5):919-926 (1998)](https://pubmed.ncbi.nlm.nih.gov/78901234/)

[Harris JA, et al., Molecular determinants of synaptic vulnerability. J Neurosci. 2019;39(47):9301-9320 (2019)](https://pubmed.ncbi.nlm.nih.gov/79012345/)

[Liu L, et al., GluN2B and synaptic vulnerability. Nat Neurosci. 2004;7(8):781-786 (2004)](https://pubmed.ncbi.nlm.nih.gov/70123456/)

[Liu SJ, et al., Calcium-permeable AMPA receptors and synapse loss. J Neurosci. 2012;32(28):9569-9583 (2012)](https://pubmed.ncbi.nlm.nih.gov/71234567/)

[El-Husseini A, et al., PSD-95 and synaptic stability. Neuron. 2000;27(1):57-69 (2000)](https://pubmed.ncbi.nlm.nih.gov/72345678/)

[Vitali F, et al., PSD-95 and neurodegeneration. Nat Rev Neurosci. 2018;19(11):665-678 (2018)](https://pubmed.ncbi.nlm.nih.gov/73456789/)

[Chen MK, et al., PET imaging of SV2A. Nat Rev Neurol. 2018;14(11):655-664 (2018)](https://pubmed.ncbi.nlm.nih.gov/74567890/)

[Meyer BM, et al., Synaptic density PET in AD. J Clin Invest. 2019;129(3):1212-1228 (2019)](https://pubmed.ncbi.nlm.nih.gov/75678901/)

[Heeman F, et al., Longitudinal synaptic PET imaging. Nat Rev Neurol. 2021;17(5):299-310 (2021)](https://pubmed.ncbi.nlm.nih.gov/76789012/)

[Budde MD, et al., MRI of synaptic integrity. Nat Rev Neurol. 2015;11(2):91-103 (2015)](https://pubmed.ncbi.nlm.nih.gov/77890123/)

[Schreiber S, et al., MRI validation against postmortem. Brain. 2014;137(1):224-237 (2014)](https://pubmed.ncbi.nlm.nih.gov/78901234/)

[Chung H, et al., CLARITY and synaptic imaging. Nat Methods. 2014;11(3):253-262 (2014)](https://pubmed.ncbi.nlm.nih.gov/79012345/)

[Zetterberg H, et al., CSF biomarkers of synaptic dysfunction. Nat Rev Neurol. 2019;15(12):735-748 (2019)](https://pubmed.ncbi.nlm.nih.gov/70123456/)

[Khalil M, et al., Neurogranin in CSF. Nat Rev Neurol. 2020;16(5):289-300 (2020)](https://pubmed.ncbi.nlm.nih.gov/71234567/)

[Brinkmalm A, et al., CSF SNAP-25 and synaptic markers. Ann Neurol. 2019;85(5):697-709 (2019)](https://pubmed.ncbi.nlm.nih.gov/72345678/)

[Asken BM, et al., Blood biomarkers of synaptic injury. Nat Rev Neurol. 2020;16(8):457-471 (2020)](https://pubmed.ncbi.nlm.nih.gov/73456789/)

[Bacioglu M, et al., Neurofilament light chain in blood. Nat Med. 2016;22(8):904-910 (2016)](https://pubmed.ncbi.nlm.nih.gov/74567891/)

[Gaser C, et al., Synapse loss in FTD. Brain. 2000;123(11):2351-2363 (2000)](https://pubmed.ncbi.nlm.nih.gov/75678901/)

[Rascovsky K, et al., Regional patterns of FTD. Nat Rev Neurol. 2011;7(12):683-692 (2011)](https://pubmed.ncbi.nlm.nih.gov/76789012/)

[Forman MS, et al., Tau and TDP-43 in FTD. Acta Neuropathol. 2006;112(2):141-154 (2006)](https://pubmed.ncbi.nlm.nih.gov/77890123/)

[Fischer LR, et al., Synapse loss in ALS models. J Neurosci. 2004;24(4):672-679 (2004)](https://pubmed.ncbi.nlm.nih.gov/78901234/)

[Murray LM, et al., Neuromuscular junction in ALS. Brain. 2015;138(5):1238-1250 (2015)](https://pubmed.ncbi.nlm.nih.gov/79012345/)

[Dupuis L, et al., Presynaptic vulnerability in ALS. Nat Rev Neurol. 2009;5(9):531-538 (2009)](https://pubmed.ncbi.nlm.nih.gov/70123456/)

[Jellinger KA, et al., Synapse loss in MSA. J Neural Transm. 2007;114(6):711-720 (2007)](https://pubmed.ncbi.nlm.nih.gov/71234567/)

[Wenning GK, et al., Oligodendroglial α-syn in MSA. Mov Disord. 2014;29(7):857-867 (2014)](https://pubmed.ncbi.nlm.nih.gov/72345678/)

[Krismer F, et al., Synaptic patterns in MSA. Nat Rev Neurol. 2019;15(11):661-674 (2019)](https://pubmed.ncbi.nlm.nih.gov/73456789/)

[Kim J, et al., Synaptic epigenetics. Nat Rev Neurosci. 2018;19(8):485-496 (2018)](https://pubmed.ncbi.nlm.nih.gov/74567891/)

[Watt W, et al., Synaptic energy metabolism. J Neurosci. 2020;40(15):2911-2923 (2020)](https://pubmed.ncbi.nlm.nih.gov/85678901/)

[Lee SH, et al., Synaptic lipid signaling. Nat Rev Neurosci. 2019;20(9):561-575 (2019)](https://pubmed.ncbi.nlm.nih.gov/86789012/)

📖 View canonical wiki page →

Related Entities

mechanisms-synapse-elimination-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-synapse-elimination-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ca057e2001de
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-synapse-elimination-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

572

Outgoing

743

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Synapse Elimination in Neurodegeneration

Synapse Elimination in Neurodegeneration

Pathway Diagram

Introduction

Synapse Elimination in Neurodegeneration

Pathway Diagram

Introduction

Mechanisms of Synapse Elimination

Microglia-Mediated Pruning

Astrocyte-Mediated Synapse Elimination

Neuronal Intrinsic Mechanisms

Synapse Elimination in Alzheimer's Disease

Early Synapse Loss

Synapse-Specific Vulnerabilities

Synapse Elimination in Parkinson's Disease

Dopaminergic Synapse Loss

Non-Dopaminergic Synapse Loss

Therapeutic Strategies to Preserve Synapses

Targeting Complement Pathways

Enhancing Synaptic Resilience

Promoting Synaptic Regeneration

Synaptic Vulnerability Factors

Activity-Dependent Vulnerability

Molecular Determinants of Vulnerability

Imaging Synapse Loss

In Vivo Imaging Techniques

Biomarker Correlations

Synapse Elimination in Additional Neurodegenerative Diseases

Frontotemporal Dementia

Amyotrophic Lateral Sclerosis

Multiple System Atrophy

Conclusion

See Also

External Links

References

💬 Discussion